Mondor’s disease as the initial presentation of breast cancer

Czech version

Authors: M. Smolár ¹; L. Juríčková ¹; D. Musová ¹; I. Daňová ¹; M. Mišánik ¹; Z. Gešvandtner Trabalková ^2,3 ; J. Miklušica ¹
Authors‘ workplace: Klinika všeobecnej, viscerálnej a transplantačnej chirurgie JLF UK a UN Martin, Slovenská republika ¹; Rádiologická klinika JLF UK a UN Martin, Slovenská republika ²; Radiologická klinika LF UP a FN Olomouc ³
Published in: Rozhl. Chir., 2026, roč. 105, č. 8, s. 404-408.
Category: Case Report
doi: https://doi.org/10.48095/ccrvch2026494

Overview

Introduction: Mondor’s disease is a rare form of superficial thrombophlebitis most commonly affecting the superficial veins of the anterior chest wall and breast. In most cases, it is a benign and self-limiting condition; however, it may occasionally be associated with breast malignancy. The aim of this paper is to present a case report of a patient in whom Mondor’s disease was the first clinical manifestation of breast cancer.

Case report: A 30-year-old female patient presented with a painful subcutaneous streak on the left breast extending caudally to the anterior abdominal wall. Clinical examination and ultrasonography confirmed Mondor’s disease with findings of superficial thrombophlebitis and absence of blood flow on Doppler imaging. Additional breast ultrasound revealed a suspicious hypoechoic lesion measuring 10.4 mm in the left breast. Core needle biopsy confirmed invasive no special type carcinoma, grade 2, hormone receptor-positive, HER2--negative, and molecular subtype Luminal A. The patient underwent breast-conserving surgery with sentinel lymph node biopsy. The postoperative course was uneventful. Complete resolution of thrombophlebitis occurred 8 weeks later.

Conclusion: Mondor’s disease may represent the first clinical manifestation of breast cancer. Patients presenting with newly developed superficial thrombophlebitis of the breast or chest wall should undergo thorough clinical and imaging evaluation of the breasts to exclude underlying malignancy. Early diagnosis enables timely oncological treatment and improves patient prognosis.

Keywords:

breast cancer – Mondor’s disease – superficial thrombophlebitis – paraneoplastic sign

Sources

1. Rountree KM, Barazi H, Aulick NF. Mondor disease. In: Treasure Island (FL): StatPearls Publishing 2022.

2. Kadyrova A, Abdullaeva A, Musaeva N et al. Clinical and ultrasound features of Mondor’s disease of the breast: a case series. Heart Vessels Transplant 2024; 8. doi: 10.24969/hvt.2023.428.

3. Koehler LA, Haddad TC, Hunter DW et al. Axillary web syndrome following breast cancer surgery: symptoms, complications, and management strategies. Breast Cancer (Dove Med Press) 2018; 11 : 13–19. doi: 10.2147/BCTT.S146635.

4. Moskovitz AH, Anderson BO, Yeung RSet al. Axillary web syndrome afteraxillary dissection. Am J Surg 2001; 181 (5): 434–439. doi: 10.1016/s0002-9610 (01) 00602-x.

5. Bergmann A, Mendes VV, de Almeida Dias R et al. Incidence and risk factors for axillary web syndrome after breast cancer surgery. Breast Cancer Res Treat 2012; 131 (3): 987–992. doi: 10.1007/s10549-011-1805-7.

6. Amano M, Shimizu T. Mondor’s disease: a review of the literature. Intern Med 2018; 57 (18): 2607–2612. doi: 10.2169/internalmedicine.0495-17.

7. Alvarez-Garrido H, Garrido-Ríos AA, Sanz--Muñoz C et al. Mondor’s disease. Clin Exp Dermatol 2009; 34 (7): 753–756. doi: 10.1111/j.1365-2230.2009.03430.x.

8. Salemis NS, Vasilara G, Lagoudianakis E. Mondor’s disease of the breast as a complication of ultrasound-guided core needle biopsy: management and review of the literature. Breast Dis 2015; 35 (1): 73–76. doi: 10.3233/BD-140374.

9. Tröbinger C, Wiedermann CJ. Bodybuilding-induced Mondor’s disease of the chest wall. Phys Ther Sport 2017; 23 : 133–135. doi: 10.1016/j.ptsp.2016.09.002.

10. Salemis NS, Merkouris S, Kimpouri K. Mondor’s disease of the breast. A retrospective review. Breast Dis 2011; 33 (3): 103–107. doi: 10.3233/BD-2012-0332.

11. Shetty MK, Watson AB. Mondor’s disease of the breast: sonographic and mammographic findings. AJR Am J Roentgenol 2001; 177 (4): 893–896. doi: 10.2214/ajr.177.4.1770893.

12. Pasta V, D’Orazi V, Sottile D et al. Breast Mondor’s disease: diagnosis and management of six new cases of this underestimated pathology. Phlebology 2015; 30 (8): 564–568. doi: 10.1177/0268355514553494.

13. Norouzi F, Eini P, Tahmasebi S. The role of NETosis in breast cancer: mechanistic insights and biomarker potential. Breast Cancer Res 2025; 27 (1): 180. doi: 10.1186/s13058-025-02136-0.

14. Catania S, Zurrida S, Veronesi P et al. Mondor’s disease and breast cancer. Cancer 1992; 69 (9): 2267–2270. doi: 10.1002/1097-0142 (199 20501) 69 : 9<2267:: aid-cncr2820690910>3.0.co; 2-u.

15. Mayor M, Burón I, de Mora JC et al. Mondor’s disease. Int J Dermatol 2000; 39 (12): 922–925. doi: 10.1046/j.1365-4362.2000.00018.x.

16. Yanik B, Conkbayir I, Oner O et al. Imaging findings in Mondor’s disease. J Clin Ultrasound 2003; 31 (2): 103–107. doi: 10.1002/jcu.10134.

17. Laroche JP, Galanaud J, Labau D et al. Mondor’s disease: what’s new since 1939? Thromb Res 2012; 130 (Suppl 1): S56–S58. doi: 10.1016/j.thromres.2012.08.276.

18. Kikano GE, Caceres VM, Sebas JA. Superficial thrombophlebitis of the anterior chest wall (Mondor’s disease). J Fam Pract 1991; 33 (6): 643–644.